FDMT vs. KRYS, IBRX, IMVT, SWTX, DNLI, TWST, ACLX, NVAX, APGE, and ADMA
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Arcellx (ACLX), Novavax (NVAX), Apogee Therapeutics (APGE), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
Krystal Biotech has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics currently has a consensus target price of $45.63, suggesting a potential upside of 102.15%. Krystal Biotech has a consensus target price of $177.63, suggesting a potential upside of 0.45%. Given 4D Molecular Therapeutics' higher possible upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Krystal Biotech.
In the previous week, 4D Molecular Therapeutics had 6 more articles in the media than Krystal Biotech. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 4 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.24 beat 4D Molecular Therapeutics' score of 0.74 indicating that Krystal Biotech is being referred to more favorably in the news media.
Krystal Biotech received 243 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 66.83% of users gave Krystal Biotech an outperform vote while only 66.04% of users gave 4D Molecular Therapeutics an outperform vote.
4D Molecular Therapeutics has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
Krystal Biotech has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -436.30%. Krystal Biotech's return on equity of -5.74% beat 4D Molecular Therapeutics' return on equity.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 7.3% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 14.1% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Krystal Biotech beats 4D Molecular Therapeutics on 12 of the 17 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
